Carsten Brunn
Chief Executive Officer chez Cartesian Therapeutics, Inc.
Fortune : 170 271 $ au 31/03/2024
Profil
Carsten Brunn currently works at Cartesian Therapeutics, Inc. (United States), as President & Chief Executive Officer from 2023, Cartesian Therapeutics, Inc., as President & Chief Executive Officer from 2023, and Biotechnology Innovation Organization, as Director.
Dr. Brunn also formerly worked at Selecta Biosciences, Inc., as President, Chief Executive Officer & Director, European Federation of Pharmaceutical Industries & Assns, as Chairman-Japan Region from 2014 to 2016, Surface Oncology, Inc., as Director from 2022 to 2023, Bayer Pharmaceuticals Corp., as President-Americas Region, and Bayer Yakuhin Ltd., as President from 2013 to 2016.
Dr. Brunn received his graduate degree from the University of Freiburg and doctorate degree from the University of Hamburg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,16% | 15/01/2024 | 261 956 ( 0,16% ) | 170 271 $ | 31/03/2024 |
Postes actifs de Carsten Brunn
| Sociétés | Poste | Début |
|---|---|---|
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Cartesian Therapeutics, Inc.
 Cartesian Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cartesian Therapeutics, Inc. manufacturers biological products. The company was founded by Murat Kalayoglu and Michael Singer in 2016 and is headquartered in Gaithersburg, MD. | Chief Executive Officer | 01/11/2023 |
Anciens postes connus de Carsten Brunn
| Sociétés | Poste | Fin |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Director/Board Member | 08/09/2023 |
Bayer Yakuhin Ltd.
 Bayer Yakuhin Ltd. Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Bayer Yakuhin Ltd. is a Japanese company that manufactures pharmaceuticals and diagnostic substances. The private company is based in Osaka, Japan. | President | 01/12/2016 |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Corporate Officer/Principal | 01/12/2016 |
| Bayer Pharmaceuticals Corp. | Corporate Officer/Principal | - |
| CARTESIAN THERAPEUTICS, INC. | Chief Executive Officer | - |
Formation de Carsten Brunn
| University of Freiburg | Graduate Degree |
| University of Hamburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
| Bayer Pharmaceuticals Corp. | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
Bayer Yakuhin Ltd.
Bayer Yakuhin Ltd. Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Bayer Yakuhin Ltd. is a Japanese company that manufactures pharmaceuticals and diagnostic substances. The private company is based in Osaka, Japan. | Health Technology |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Commercial Services |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cartesian Therapeutics, Inc. manufacturers biological products. The company was founded by Murat Kalayoglu and Michael Singer in 2016 and is headquartered in Gaithersburg, MD. | Commercial Services |
